HC Wainwright reissued their neutral rating on shares of Zura Bio (NASDAQ:ZURA – Free Report) in a report released on Monday ...

Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company’s recent issuance of a U.S. patent ...

CARGO Therapeutics (CRGX) announced that its first abstract on CRG-023 will be presented as a poster at the upcoming 66th American Society of ...

然而CAR T疗法针对胶质母细胞瘤（Glioblastoma，GBM）在内的诸多实体瘤效果却十分有限。为了进一步提升CAR T细胞在治疗实体瘤时的疗效，当前大多数研究致力于改良CAR ...

Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet”) (NASDAQ: SONN), a clinical-stage company developing ...

该研究开发了一种策略，利用从头设计的结合蛋白（de novo-designed binder，DNDB）代替典型的scFv作为肿瘤表面抗原结合域，以增强CAR-T细胞的抗肿瘤潜力。

The A10m3 scFv was selected to bind both at normal pH, as well as at the acidic pH that is typically found in the TME. The ...

西湖实验室研究员谢琦与研究员曹龙兴为共同通讯作者。西湖大学生命科学学院博士生夏真和博士生金启涵为本文的共同第一 ...